Despite showing an enhanced achievement rate of pCR in patients with high-risk, HR-positive/HER2-negative stage II/III breast cancer (n = 75), the regimen did not meet the pre-specified threshold for graduation [139]. This evidence concerns the gene ERBB2 and breast carcinoma.